Health Catalyst, Inc. HCAT
We take great care to ensure that the data presented and summarized in this overview for Health Catalyst, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HCAT
View all-
Black Rock Inc. New York, NY5.43MShares$24.7 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN5.24MShares$23.8 Million3.62% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.39MShares$20 Million0.0% of portfolio
-
Impax Asset Management Group PLC2.75MShares$12.5 Million0.1% of portfolio
-
Daventry Group, LP New York, NY2.51MShares$11.4 Million6.78% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.02MShares$9.19 Million0.06% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.99MShares$9.03 Million0.01% of portfolio
-
Primecap Management CO Pasadena, CA1.93MShares$8.79 Million0.01% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.89MShares$8.6 Million0.32% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.59MShares$7.24 Million0.0% of portfolio
Latest Institutional Activity in HCAT
Top Purchases
Top Sells
About HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Insider Transactions at HCAT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 06
2025
|
Benjamin Landry General Counsel |
SELL
Open market or private sale
|
Direct |
13,827
-7.93%
|
$55,308
$4.55 P/Share
|
|
Mar 05
2025
|
Daniel Le Sueur Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,902
-7.25%
|
$67,608
$4.52 P/Share
|
|
Mar 03
2025
|
Daniel D. Burton Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,677
-2.25%
|
$134,708
$4.58 P/Share
|
|
Mar 03
2025
|
Linda Llewelyn Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,525
-4.52%
|
$30,100
$4.58 P/Share
|
|
Mar 03
2025
|
Kevin Lee Freeman Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,800
-2.73%
|
$43,200
$4.58 P/Share
|
|
Mar 03
2025
|
Jason Alger Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,304
-2.61%
|
$29,216
$4.58 P/Share
|
|
Mar 03
2025
|
Benjamin Landry General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
9,024
-4.92%
|
$36,096
$4.58 P/Share
|
|
Mar 03
2025
|
Daniel Le Sueur Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,232
-3.81%
|
$36,928
$4.58 P/Share
|
|
Mar 01
2025
|
Duncan Gallagher |
BUY
Grant, award, or other acquisition
|
Direct |
3,033
+3.99%
|
-
|
|
Mar 01
2025
|
Julie Larson Green |
BUY
Grant, award, or other acquisition
|
Direct |
2,450
+3.32%
|
-
|
|
Feb 20
2025
|
Benjamin Landry General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
111,038
+21.68%
|
-
|
|
Feb 20
2025
|
Jason Alger Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
192,950
+22.22%
|
-
|
|
Feb 20
2025
|
Kevin Lee Freeman Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
158,262
+15.75%
|
-
|
|
Feb 20
2025
|
Daniel D. Burton Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
371,437
+11.0%
|
-
|
|
Feb 20
2025
|
Daniel Le Sueur Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
156,340
+21.51%
|
-
|
|
Feb 20
2025
|
Linda Llewelyn Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,750
+18.71%
|
-
|
|
Feb 18
2025
|
Linda Llewelyn Chief People Officer |
SELL
Open market or private sale
|
Direct |
6,441
-6.98%
|
$32,205
$5.43 P/Share
|
|
Feb 05
2025
|
Daniel Le Sueur Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,209
-5.71%
|
$26,045
$5.76 P/Share
|
|
Jan 15
2025
|
Linda Llewelyn Chief People Officer |
SELL
Open market or private sale
|
Direct |
6,442
-6.53%
|
$32,210
$5.8 P/Share
|
|
Jan 06
2025
|
Benjamin Landry General Counsel |
SELL
Open market or private sale
|
Direct |
2,500
-3.34%
|
$17,500
$7.52 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.22M shares |
|---|
| Payment of exercise price or tax liability | 182K shares |
|---|---|
| Open market or private sale | 232K shares |